Press Releases

• Juvaris BioTherapeutics Announces License to Colby Pharmaceutical Company for JVRS-100 and CLDC (Cationic Lipid-DNA Complex) Platform for Human Health — 09.09.11

• Juvaris BioTherapeutics Announces Publication of Preclinical Anti-Leukemic Effects of JVRS-100 Immunotherapy — 09.30.10

• Juvaris BioTherapeutics Completes Second Close on $25 million Series B Financing — 01.27.10

• Juvaris BioTherapeutics Initiates Phase 2 Study of Influenza Vaccine Adjuvant in Elderly Population — 11.02.09

• Juvaris BioTherapeutics Announces First Close on $25 million Series B Financing — 09.17.09

• Juvaris BioTherapeutics Announces Strategic Collaboration with Antigen Discovery, Inc. — 06.29.09

• Juvaris BioTherapeutics’ Universal Influenza Vaccine Protects from Lethal H1N1 and H3N2 Challenges in Pre-Clinical Studies — 05.08.09

• Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial — 04.27.09

• Juvaris BioTherapeutics Announces Progress in Alliance with Bayer Animal Health — 01.09.09

• Juvaris BioTherapeutics Announces Positive Data from Clinical Trial of JVRS-100 Adjuvanted Flu Vaccine — 01.08.09